Open Letter to Jimmy "MrBeast" Donaldson - 27 year old YouTuber with 469 subscribers and 1.4 billion people watching his content, more than anyone else on Earth.
Subject: Teaching Young Investors the Venture-Capital Mindset Through BIEL
Hey Jimmy,
You’ve already shown millions of young people that money isn’t just something you spend—it’s something you build. With Step, you opened the door to financial literacy. The next evolution is teaching the mindset behind venture capital: spotting undervalued opportunities, understanding asymmetric risk, and learning how tiny investments can create life-changing returns.
That’s where BioElectronics Corp (BIEL) becomes the perfect real-world case study.
BIEL Is a “Venture-Capital-Style” Investment Anyone Can Afford
Most teens can’t buy into early-stage startups or private deals. But they can buy shares of a micro-cap company trading for a fraction of a penny. BIEL sits around $0.0003, which means:
$1 buys over 3,000 shares
$10 buys over 30,000 shares
$100 buys over 300,000 shares
It’s the closest thing to “venture investing for everyone,” because the barrier to entry is almost zero—but the upside, if the thesis plays out, is enormous.
This lets young investors learn the core VC lesson:
Small checks + high conviction + long time horizon = asymmetric ROI.
The Real Story: BIEL + Electrome = A Technical Marriage With Massive Optionality
BIEL isn’t just a cheap stock. It’s a company with a validated, FDA-cleared technology—PEMF therapy—that already works in the real world. ActiPatch® is a wearable device that uses micro-pulses to calm pain signaling without drugs.
The “venture-style” catalyst is the new partnership with Electrome, led by Ken Mayer, a founder with a track record of scaling and exiting companies for nine-figure sums.
Young investors get to see how a small company suddenly becomes part of a much bigger engine.
What makes this partnership a VC-style inflection point:
The Mayer Effect — A proven operator with Mayo Clinic ties and AI-driven therapy experience is taking BIEL’s tech from niche to mainstream.
Minimum Purchase Commitments - Electrome is guaranteeing volume. That’s revenue predictability - something micro-caps almost never have.
Distribution + Data + AI — BIEL provides the hardware; Electrome provides the intelligence and the go-to-market muscle.
This is exactly the kind of “technical marriage” VCs look for:
a small company with great tech plugging into a larger company with scale.
This Fits Perfectly Into Your Mission of Teaching Young People to Invest
1. A Real-World Lesson in High-Risk, High-Reward Investing
BIEL is a micro-cap. It’s volatile. It’s speculative.
But that’s the point: young investors learn how to evaluate risk, not avoid it.
You can show them:
how to research a company
how to understand catalysts
how to think in probabilities, not guarantees
how to size positions responsibly
It’s the safest way to teach the mindset of venture capital without needing accredited-investor status.
2. A Humanitarian Story That Mirrors Your Brand
You’ve cured blindness. You’ve restored hearing.
BIEL’s tech is about relieving chronic pain without opioids.
Imagine teaching financial literacy while also showing how investing can support technologies that help millions of people live pain-free.
3. A David-vs-Goliath Narrative Young Investors Love. Retail investors already frame BIEL as the underdog fighting:
Big Pharma
institutional short sellers
outdated medical gatekeeping
It’s the same energy as Step taking on traditional banks.
4. A Gamified, Educational Experience Through Step
You could turn this into a viral financial-literacy moment:
“Learn how to evaluate a micro-cap.”
“Build your first VC-style portfolio.”
“Understand asymmetric upside.”
You’re not telling kids to buy BIEL—you’re teaching them how to think.
The Story You Can Tell
“Most people think you need millions to invest like a venture capitalist. But what if you could learn the same skills with just a few dollars? Today I’m showing you how to analyze a real micro-cap company with real technology and real upside—and how to think about risk the way professionals do.”
It’s educational.
It’s empowering.
It’s aligned with your mission.
And it’s built around a real company with a real catalyst.
Regards,
Bielionaire
Subject: Teaching Young Investors the Venture-Capital Mindset Through BIEL
Hey Jimmy,
You’ve already shown millions of young people that money isn’t just something you spend—it’s something you build. With Step, you opened the door to financial literacy. The next evolution is teaching the mindset behind venture capital: spotting undervalued opportunities, understanding asymmetric risk, and learning how tiny investments can create life-changing returns.
That’s where BioElectronics Corp (BIEL) becomes the perfect real-world case study.
BIEL Is a “Venture-Capital-Style” Investment Anyone Can Afford
Most teens can’t buy into early-stage startups or private deals. But they can buy shares of a micro-cap company trading for a fraction of a penny. BIEL sits around $0.0003, which means:
$1 buys over 3,000 shares
$10 buys over 30,000 shares
$100 buys over 300,000 shares
It’s the closest thing to “venture investing for everyone,” because the barrier to entry is almost zero—but the upside, if the thesis plays out, is enormous.
This lets young investors learn the core VC lesson:
Small checks + high conviction + long time horizon = asymmetric ROI.
The Real Story: BIEL + Electrome = A Technical Marriage With Massive Optionality
BIEL isn’t just a cheap stock. It’s a company with a validated, FDA-cleared technology—PEMF therapy—that already works in the real world. ActiPatch® is a wearable device that uses micro-pulses to calm pain signaling without drugs.
The “venture-style” catalyst is the new partnership with Electrome, led by Ken Mayer, a founder with a track record of scaling and exiting companies for nine-figure sums.
Young investors get to see how a small company suddenly becomes part of a much bigger engine.
What makes this partnership a VC-style inflection point:
The Mayer Effect — A proven operator with Mayo Clinic ties and AI-driven therapy experience is taking BIEL’s tech from niche to mainstream.
Minimum Purchase Commitments - Electrome is guaranteeing volume. That’s revenue predictability - something micro-caps almost never have.
Distribution + Data + AI — BIEL provides the hardware; Electrome provides the intelligence and the go-to-market muscle.
This is exactly the kind of “technical marriage” VCs look for:
a small company with great tech plugging into a larger company with scale.
This Fits Perfectly Into Your Mission of Teaching Young People to Invest
1. A Real-World Lesson in High-Risk, High-Reward Investing
BIEL is a micro-cap. It’s volatile. It’s speculative.
But that’s the point: young investors learn how to evaluate risk, not avoid it.
You can show them:
how to research a company
how to understand catalysts
how to think in probabilities, not guarantees
how to size positions responsibly
It’s the safest way to teach the mindset of venture capital without needing accredited-investor status.
2. A Humanitarian Story That Mirrors Your Brand
You’ve cured blindness. You’ve restored hearing.
BIEL’s tech is about relieving chronic pain without opioids.
Imagine teaching financial literacy while also showing how investing can support technologies that help millions of people live pain-free.
3. A David-vs-Goliath Narrative Young Investors Love. Retail investors already frame BIEL as the underdog fighting:
Big Pharma
institutional short sellers
outdated medical gatekeeping
It’s the same energy as Step taking on traditional banks.
4. A Gamified, Educational Experience Through Step
You could turn this into a viral financial-literacy moment:
“Learn how to evaluate a micro-cap.”
“Build your first VC-style portfolio.”
“Understand asymmetric upside.”
You’re not telling kids to buy BIEL—you’re teaching them how to think.
The Story You Can Tell
“Most people think you need millions to invest like a venture capitalist. But what if you could learn the same skills with just a few dollars? Today I’m showing you how to analyze a real micro-cap company with real technology and real upside—and how to think about risk the way professionals do.”
It’s educational.
It’s empowering.
It’s aligned with your mission.
And it’s built around a real company with a real catalyst.
Regards,
Bielionaire
1
